Study of an oral drug for solid tumors or glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either an advanced solid tumor that standard treatments no longer work for, or you have been newly diagnosed with glioblastoma.
- Your tumor can be measured on scans (like CT, MRI).
- You are able to walk and take care of yourself (ECOG score 0-2 for solid tumors, Karnofsky score 60 or more for glioblastoma).
- Your liver, kidneys, and blood cell counts are within a certain range (tests will be done to check this).
- You have not had certain heart or blood clot problems in the last 6 months.
- If you could become pregnant, you agree to use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a continuation study for patients who completed or are in the parent trial testing NBM-BMX (an experimental drug) combined with temozolomide (a standard brain-tumor chemotherapy) for newly diagnosed glioblastoma. If you tolerated the earlier treatment well and your doctor believes you could benefit, you may continue the same drugs in this rollover study.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This study tests an experimental treatment given after the standard first treatment (chemotherapy and radiation) for newly diagnosed glioblastoma, a type of brain cancer. It aims to see if this extra treatment helps keep the cancer from coming back.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.